- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04393727
Transfusion of Convalescent Plasma for the Early Treatment of Patients With COVID-19 (TSUNAMI)
Transfusion of Convalescent Plasma for the Early Treatment of pneumonIa Due to SARSCoV2: a Multicenter Open Label Randomized Control Trial
No specific therapeutic agents or vaccines for COVID-19 are available. Several therapies, are under investigation, but the antiviral efficacy of these drugs is not yet known. The use of convalescent plasma was recommended as an empirical treatment during outbreaks of Ebola virus in 2014, and a protocol for treatment of Middle East respiratory syndrome coronavirus with convalescent plasma was established in 2015. Accordingly, we hypothesized that use of convalescent plasma transfusion could be beneficial in patients infected with SARS-CoV-2.
This is a multicenter prospective randomized clinical trial to evaluate safety and efficacy of early use of convalescent plasma in patients with SARS-CoV2 pneumonia.
Primary endpoint will be the efficacy, evaluated as the need of invasive mechanical ventilation defined by PaO2/FiO2 ratio <150.
Secondary endpoints will be: mortality rates, time to invasive mechanical ventilation, time to virological cure, length of hospital stay, toxicity.
Patients with SARS-CoV2 pneumonia not requiring mechanical ventilation (both non invasive and invasive) will be randomized 1:1 to receive or not convalescent plasma. Patients in the plasma group will receive 200 ml of convalescent plasma, continuing already administered standard therapy, while patients in the control group will continue to receive the standard therapy. A rescue therapy will be allowed in case of clinical worsening.
Patients will be followed-up until 30 days from randomization.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a multicenter prospective randomized open-label clinical trials. Patients with pneumonia due to SARS-CoV-2 will be included and randomized to receive or not convalescent plasma.
Convalescent plasma will be collected by cured patients with previous diagnosis of COVID-19. More specifically, inclusion and exclusion criteria for donors will be the following.
Inclusion criteria for donors:
- age > 18 and <60 years
- confirmed diagnosis of COVID-19: PCR on nasopharynx swab or positive IgG
- presence of 2 negative nasopharynx swabs for patients with previous positive swab and presence of 1 negative nasopharynx swab for patients with positive IgG
Exclusion criteria for donors:
- age < 18 ys or >60 ys
- other conditions that controindicate blood donation
Collected plasma will undergo all procedures for blood preparation. Plasma will be tested with enzyme-linked immunosorbent assay (ELISA) and neutralizing antibody titers.
Patients eligible for the study will be selected among hospitalized patients with SARS-CoV2 pneumonia. More specifically, the following criteria will used for inclusion in the study.
Inclusion criteria for recipients:
- age >18 ys
- confirmed diagnosis of SARS-CoV2 pneumonia
- PaO2/FiO2 200-350
Exclusion criteria for recipients:
- PaO2/FiO2 <200
- need of non invasive or invasive mechanical ventilation
Patients will be randomized 1:1 to receive or not convalescent plasma. All patients will be followed-up for 30 days after randomization.
Primary endpoint will be the need of mechanical ventilation, defined as PaO2/FiO2 <150.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Pisa, Italy, 56124
- Azienda Ospedaliero Universitaria Pisana
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Any gender
- Age > 18 years on day of signing informed consent
- Informed written consent for participation in the study
- Virological diagnosis of SARS-CoV-2 infection (real-time PCR)
- Hospitalized due to clinical instrumental diagnosis of pneumonia
- PaO2/FiO2 ratio 200-350
Exclusion Criteria:
- mechanical ventilation (both invasive and non-invasive)
- PaO2/FiO2<200
- known hypersensitivity to immunoglobulin or blood components
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention
Patients in the intervention group will receive 200 cc of convalescent plasma
|
Convalescent plasma will be collected by healthy donors, cured by COVID-19 and, after standard preparation and dosage of neutralizing antibodies, will be administered to patients with SARS-CoV2 pneumonia
|
No Intervention: Control
Patients will continue to receive standard therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Need of invasive mechanical ventilation
Time Frame: 30 days
|
Need of invasive mechanical ventilation defined as PaO2/FiO2 <150
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mortality rates
Time Frame: 30 days
|
Thirty-day mortality rates
|
30 days
|
Time to invasive mechanical ventilation
Time Frame: 30 days
|
Days from randomization to invasive mechanical ventilation
|
30 days
|
Time to virologic cure
Time Frame: 30 days
|
Days from randomization to virologic cure defined as 2 consecutive negative nasopharynx swabs
|
30 days
|
Length of hospital stay
Time Frame: 30 days
|
Days from randomization to discharge or death
|
30 days
|
Adverse events
Time Frame: 30 days
|
Occurrence of adverse events
|
30 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Francesco Menichetti, Azienda Ospedaliero, Universitaria Pisana
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- Tsunami
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on SARS-CoV 2
-
Argorna Pharmaceuticals Co., LTDCompleted
-
Argorna Pharmaceuticals Co., LTDCompleted
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Active, not recruiting
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...Active, not recruiting
-
Arcturus Therapeutics, Inc.Terminated
-
University Hospital Inselspital, BerneUniversity of Bern; Lucerne University of Applied Sciences and ArtsCompleted
-
Centre Hospitalier Universitaire DijonUnknown
-
AIM Vaccine Co., Ltd.Zhejiang Provincial Center for Disease Control and PreventionNot yet recruiting
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...Not yet recruiting
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical CollegeActive, not recruiting
Clinical Trials on CONVALESCENT PLASMA
-
Noah MerinJohns Hopkins UniversityTerminatedCovid-19 | Sars-CoV2United States
-
Gailen D. Marshall Jr., MD PhDUniversity of Mississippi Medical CenterCompleted
-
Federal Research Clinical Center of Federal Medical...Completed
-
Thomas BenfieldTerminatedCOVID | Corona Virus Infection | Viral PneumoniaDenmark
-
Henry Ford Health SystemCompletedCoronavirus Infection | COVID | CoronavirusUnited States
-
Universidad Peruana Cayetano HerediaCompleted
-
Ministry of Health and Population, EgyptCompletedCovid19 | Plasma | Convalescent Plasma | Immunoglobulins | EgyptEgypt
-
Southeast University, ChinaCompleted
-
Lahore General HospitalUnknown